The list of UK biotechs deciding to abandon listings on the AIM exchange in the UK just lengthened, after BiVictriX said it wants to cancel its shares and go private.
A promising vaccine candidate for Rift Valley fever (RVF) has been advanced into a phase 2 trial in Kenya, the first time that a shot has reached this stage of development in a country wher